Moderna Stock Plummets 4795% in Volume Ranking 493rd After FDA Guidance on Omicron Booster

On July 24, 2025, Moderna's trading volume was $227 million, a significant decrease of 47.95% from the previous day, ranking 493rd in the day's stock market. Moderna (MRNA) closed at $1.90.

Moderna's stock price experienced a decline due to the company's decision to withdraw its application for a booster shot for the Omicron variant. This move was influenced by the U.S. Food and Drug Administration's (FDA) recommendation to prioritize the development of a new vaccine that targets the latest COVID-19 variants. The FDA's guidance emphasized the importance of focusing on vaccines that can provide broader protection against emerging strains, rather than targeting specific variants that may become less prevalent over time.

Additionally, Moderna's stock was affected by the company's announcement that it will not pursue a booster shot for the Omicron variant. This decision was made in response to the FDA's recommendation to prioritize the development of a new vaccine that targets the latest COVID-19 variants. The FDA's guidance emphasized the importance of focusing on vaccines that can provide broader protection against emerging strains, rather than targeting specific variants that may become less prevalent over time.

Moderna's stock price also saw a decline due to the company's decision to withdraw its application for a booster shot for the Omicron variant. This move was influenced by the U.S. Food and Drug Administration's (FDA) recommendation to prioritize the development of a new vaccine that targets the latest COVID-19 variants. The FDA's guidance emphasized the importance of focusing on vaccines that can provide broader protection against emerging strains, rather than targeting specific variants that may become less prevalent over time.